Articles tagged with Cystic Fibrosis
A new study reveals that human airways rely on a 'brush-like' layer to clear mucus, which protects cells from sticky mucus and captures foreign particles. The findings may lead to the development of novel therapies for lung diseases.
Researchers have discovered a genetic process that can restore function to a defective protein responsible for cystic fibrosis. By manipulating a specific microRNA network, they were able to partially restore the protein's function and increase its production.
Researchers have identified a new strategy to thin thick mucus in cystic fibrosis and COPD using the SPLUNC1 protein and its synthetic derivatives. This may lead to improved mucus clearance and better lung function for those affected.
Researchers discovered rare variations in the DCTN4 gene among cystic fibrosis patients with early, chronic airway infections. The study suggests that exome sequencing can identify genetic factors behind complex traits like obesity and heart disease.
A study by University of Iowa researchers found that cystic fibrosis makes airways more acidic, reducing bacterial killing. Making the airway liquid less acidic with baking soda restores normal bacterial killing levels.
Dr. David Feola, a University of Kentucky College of Pharmacy faculty member, has received a five-year, $1.8 million grant from the National Institutes of Health to investigate immune responses in the lungs that may lead to medical treatments for cystic fibrosis and other chronic pulmonary inflammatory conditions.
A new NIH-funded study finds that concentrated saline therapy does not reduce antibiotic use in infants and preschoolers with cystic fibrosis. The study highlights the need for more research on treatments tailored to younger children with this disease.
A randomized trial found that hypertonic saline did not reduce the rate of pulmonary exacerbations in young children with cystic fibrosis. The study also showed no significant effects on secondary end points such as weight and respiratory symptoms.
A team of scientists at Duke University developed software to design molecules that block a protein-protein interaction key to cystic fibrosis. The best molecule increased CFTR activity by 12% in human cells with the disease mutation.
Researchers at Massachusetts General Hospital have created human lung surface tissue in a dish, containing the delta-508 and G551D mutations responsible for most CF cases. This breakthrough enables drug screening on genuine human cells, paving the way for a potential therapy to control cystic fibrosis.
Researchers have discovered gene variations that predispose cystic fibrosis patients to develop an intestinal blockage while still in the uterus. These variants involve genes responsible for ion transport in the lower end of the small intestine, increasing the risk of meconium ileus and serious health problems.
Researchers have discovered multiple genes associated with meconium ileus, a severe intestinal obstruction present at birth in CF patients. This finding suggests the possibility of personalized approaches to treatment and novel therapeutic targets for individuals with cystic fibrosis.
Researchers found that suppressing bacterial communities with antibiotics may actually help treatment-resistant bacteria flourish, leading to more infections. The study suggests new avenues for developing more effective treatments and improving patient outcomes.
A recent study suggests that restoring normal function to the mutant gene product responsible for cystic fibrosis requires correcting two distinct structural defects. This finding could lead to more effective therapeutic strategies for CF in the future.
A new study has found that the lung clearance index (LCI) is a sensitive non-invasive marker of early lung disease in young children with cystic fibrosis. LCI was elevated in children with CF, especially in those with airway inflammation and Pseudomonas aeruginosa infection.
A new study found that adding inhaled dry powder mannitol to standard therapy for cystic fibrosis improved lung function over 52 weeks. The treatment showed a significant improvement in forced expiratory volume in one second (FEV1) and fewer pulmonary exacerbations compared to the control group.
A Wayne State University research team is working on a roadmap for identifying novel therapeutic targets to restore function to the mutated CFTR protein in cystic fibrosis patients. The goal is to alleviate severe lung and bowel problems associated with the disease.
A pivotal Phase 3 clinical trial found that ivacaftor provides sustained improvement in lung function, growth, and other signs and symptoms for cystic fibrosis patients. The therapy targets the underlying cause of CF, restoring balance on airway surfaces.
Four Michigan State University researchers are working on new projects to combat cystic fibrosis, using funds from the $110,000 grant from Hunt for a Cure. The studies aim to develop new treatments and prevent bacterial infections, with a focus on understanding the role of molecules, genes, and biofilms in the disease.
A new study found that cigarette smoke affects the lungs in a way similar to cystic fibrosis, causing dry cough and chronic bronchitis. The study suggests that treatments for cystic fibrosis might also help people with smoking-related diseases.
The Woods Hole Oceanographic Institution is collaborating with the Flatley Discovery Lab to investigate and supply marine microbial extracts as possible treatments for cystic fibrosis. The collaboration aims to stimulate the mutated CFTR gene to work normally, offering a new approach beyond traditional antibiotic treatment.
Researchers have developed a technique to observe cystic fibrosis cellular intricacies, revealing the role of CFTR in regulating ENaC activity. The study found that healthy CFTR prevents ENaC overactivity, while defective CFTR allows it to occur.
Researchers have discovered a protein called ubiquitin ligase Nedd4L as a new regulator of cystic fibrosis. Mice lacking Nedd4L in the lung developed cystic fibrosis-like disease, highlighting a promising therapeutic target. Enhancing Nedd4L function or inhibiting ENaC may alleviate symptoms of the disease.
Cystic fibrosis is caused by a mutated gene affecting ion transport across cell membranes. Researchers have discovered an unexpected way to send mutant proteins to the surface to restore ion transport. Higher levels of GRASP65 escort mutant CFTR channels to the cell surface, dramatically extending the lives of mice with cystic fibrosis.
Research confirms long-term azithromycin treatment increases infection with nontuberculous mycobacteria, a serious complication in cystic fibrosis. Azithromycin blocks autophagy, impairing immune cells' ability to kill bacteria.
Researchers have identified a protein called MYLIP as a potential new target for lowering LDL cholesterol levels, which are associated with atherosclerotic cardiovascular disease. Additionally, platinum-based drugs have been found to promote anticancer immune responses by disrupting the mechanisms used by tumors to inhibit immune cells.
A study found that invasive diagnostic procedures for infants with cystic fibrosis do not reduce lung-damaging infections or structural lung injury. The treatment, which involved culturing fluid samples from the lungs, did not demonstrate clinical benefits but led to increased risks of adverse events.
Researchers at UCLA have identified a new stem cell that plays a vital role in repairing the large airways of the lungs. The discovery has implications for understanding airway diseases and developing novel cell-based therapies.
Notch signaling pathway plays a crucial role in controlling the differentiation of airway basal stem cells, with high levels leading to secretory cells and low levels resulting in ciliated cells. The findings have implications for developing therapies for airway diseases, which are a leading cause of death worldwide.
Cystic fibrosis patients who played video games that controlled their breath improved their ability to take deep breaths and increase breathing maneuvers. The study used spirometer games to encourage children to practice huffing techniques.
Combination therapy of loperamide and minocycline may provide a safer method for treating devastating lung infections in people with cystic fibrosis. The approach could cut drug development time in half, offering new hope for those affected by this genetic disease.
Dr. Hongwei Yu's lab will explore the factors controlling mucus overproduction and develop a treatment to inhibit alginate biofilm formation in CF patients. The grant aims to improve treatment of bacterial infections and enhance quality of life for CF patients.
Researchers have created a pig model that genetically replicates the most common form of cystic fibrosis, revealing how the CF protein is misprocessed and leads to disease symptoms. The study suggests that a small amount of active CFTR protein activity is not sufficient to prevent disease in pigs.
Researchers at the University of Liverpool identified a particularly virulent strain of Pseudomonas aeruginosa, known as the 'superbug', that causes aggressive infections in cystic fibrosis patients. The team used new DNA sequencing technology to understand how the bacteria adapts to infect patients and develop targeted treatments.
A £1.74 million grant from the National Institutes of Health has been awarded to improve treatment outcomes for Cystic Fibrosis patients by studying the role of anaerobes in lung damage.
A phase 3 clinical trial found that denufosol can help delay the progression of lung disease in CF patients by preventing mucus formation. The study showed improved lung exhalation rates and reduced symptoms in patients receiving denufosol compared to those on placebo.
The Cystic Fibrosis Technology Initiative aims to create new medicines for cystic fibrosis, a genetic disorder affecting thousands of Canadians. The initiative will assess promising discoveries and develop them using CDRD's advanced drug development platform.
A small study shows that VX-770, targeting the defective CFTR protein, improves lung function and other key indicators in cystic fibrosis patients. The drug has shown promise for treating the root cause of the disease.
Researchers discovered that a genetic error causing cystic fibrosis also affects the flow of sodium ions, preventing excessive mucus buildup. This finding has implications for developing better therapies for the disease.
A team of researchers has generated 100 new lines of human induced pluripotent stem cells (iPSCs) from individuals with lung diseases, including cystic fibrosis and emphysema. The new stem cell lines could lead to new treatments for these debilitating diseases.
A University of Missouri researcher has made significant progress in understanding cystic fibrosis by identifying the mutations that cause it. By manipulating the sensor of the channel protein, scientists may be able to develop a drug design that can eventually lead to a 'real cure' for this fatal genetic disease.
A UCLA-led research team found that bacteria can stand upright and 'walk' during biofilm formation, allowing them to explore surfaces more effectively. This unique behavior is enabled by type IV pili appendages and plays a critical role in bacterial detachment from surfaces.
Researchers have found a possible new target for fighting cystic fibrosis, exploiting the crosstalk between two chloride ion channels in mucous gland cells. The study suggests that activating one channel could compensate for the lack of CFTR functionality in affected cells.
Researchers found that vitamin D can reduce the production of a protein driving an allergic response in cystic fibrosis patients and increase production of proteins promoting tolerance. The findings support a potential clinical trial to prevent or treat Allergic Bronchopulmonary Aspergillosis (ABPA) in these patients.
Two independent research groups demonstrate that induced pluripotent stem cells can be used to model diseases of the liver and generate functional hepatocytes with proliferative capabilities. These findings expand our understanding of iPS cell technology's potential for cell replacement therapy and modeling human disease.
Research at LSU Health Sciences Center found that vitamin D can reduce allergic responses to Aspergillus fumigatus, a common mold that causes severe allergic symptoms in asthmatics and Cystic Fibrosis patients. Vitamin D also increased production of proteins promoting tolerance.
Neural stem cells can repair damaged spinal cords by promoting nerve cell generation, restoring hind limb function in mice. Vitamin D may help prevent allergic bronchopulmonary aspergillosis in cystic fibrosis patients.
A major JAMA study found that patients with cystic fibrosis who tested positive for MRSA had a significantly higher risk of death compared to those without the infection. The study, which tracked over 19,000 CF patients, showed an approximate 1.3 times greater risk of death among those with detected MRSA.
Patients with cystic fibrosis who test positive for MRSA in their respiratory tract have a higher risk of death. The study found that MRSA was associated with a 27.7 deaths per 1000 patient-years, compared to 18.3 for those without the bacteria.
Research on older cystic fibrosis patients reveals significant differences in disease outcomes between males and females, with females living longer and having delayed but equally severe disease. The study's findings provide valuable insights into the future treatment of cystic fibrosis as this population continues to grow.
Researchers found MP-376 reduced P. aeruginosa density and improved lung function in CF patients, with the highest dose showing the most significant effect. The treatment was well-tolerated and showed a 79% reduction in need for other antimicrobials.
A new experimental drug called ataluren has shown promise in treating cystic fibrosis and over 2,400 genetic disorders caused by nonsense mutations. The drug works by restoring up to 29% of normal protein function in mice with cystic fibrosis, offering hope for improved treatment options.
Researchers have made significant progress in treating inherited diseases by suppressing DNA mutations, with a promising experimental drug ataluren showing potential for cystic fibrosis treatment. The drug's selectiveness offers hope for targeting specific disease-causing mutations while sparing healthy genes.
A recent study published in the World Journal of Gastroenterology reports successful treatment of cystic fibrosis (CF) and Crohn's disease using infliximab. The therapy improved colonic lesions and overall condition without compromising lung function, suggesting a potential anti-inflammatory effect on both colon and lung.
A multinational study found that cystic fibrosis patients from EU countries live longer than those in neighboring non-EU countries. The data suggest a higher proportion of patients surviving to age 40 and a larger CF population if demographic profiles were comparable to EU countries.
A defective signaling pathway for PPAR-γ contributes to cystic fibrosis disease severity. Correction of the pathway reduces symptoms in mice, suggesting a potential therapeutic target.
A recent study led by Dr. Lucas Hoffman found that Pseudomonas aeruginosa, a common pathogen in cystic fibrosis lung infections, can resist powerful antibiotics due to adapting to the clogged airways. The mutation enables the bacteria to thrive in viscous lung secretions and survive oxidative stress caused by antibiotic treatment.
A team of researchers has made a breakthrough discovery about the defective protein that causes cystic fibrosis, understanding its special relationship with pH levels inside cells. By regulating acid-base balance, the protein controls salt transport and cell survival, offering hope for developing new therapies to restore function.
A study in northeastern Italy found a decrease in cystic fibrosis incidence with increased carrier screening, particularly in the eastern region. The rate of decrease was greater in the eastern region due to extensive use of mutation analysis.
A Scripps Research Institute team restored partial function to lung cells collected from patients with cystic fibrosis, opening a door to new therapies for this and other chronic diseases. The breakthrough uses a compound called suberoylanilide hydroxamic acid (SAHA) to correct protein misfolding.